39800-25-4

Usage

General Description

The chemical "2-[bis(2-chloroethyl)amino]-3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-4-yl hydroperoxide" is a potent and toxic oxazaphosphorine compound. It is a derivative of nitrogen mustard and contains a hydroperoxide group, which makes it highly reactive and potentially dangerous. This chemical has been studied for its potential use in cancer chemotherapy due to its ability to inhibit DNA replication and lead to cell death. However, it is also highly toxic to healthy cells and can cause severe side effects. Therefore, it is primarily used in research and is not widely available for clinical use. Use and handling of this chemical should be done with extreme caution and in accordance with strict safety protocols.

Upstream product

• 22089-22-1 trofosfamide 

Relevant academic research and scientific papers

Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative.

The hydroperoxy and several alkylthio derivatives of the antitumor agents cyclophosphamide (2-bis(2-chloroethyl)amino tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide), ifosfamide (3-(2-chloroethyl)-2-(2-chloroethylamino)tetrahydro-2H-1,3,1-oxazaphosphorine 2-oxide) and trofosfamide (3-(2-chloroethyl)-2-(bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) were characterized by electron impact and field desorption mass spectrometry. The compounds, which are stabilized derivatives of the activated hydroxylated intermediates of cyclophosphamide (ifosfamide, trofosfamide), could be identified as 4-hydroperoxy and 4-alkylthio oxazaphosphorines. The existence of diastereomers of these products was demonstrated by thin-layer chromatography and f.d. mass spectra. Derivatization with benzylmercaptan was found to be an appropriate method for the quantitative isolation and mass spectral identification of the activated metabolic intermediates of cyclophosphamide from biological material. Using this reaction, 4-hydroxycyclophosphamide and its acyclic tautomer, aldophosphamide, which are too unstable for direct identification, were detected in urine and serum of patients treated with 3H-cyclophosphamide.